stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) EV/Sales
As of 5 November 2026, Praxis Precision Medicines, Inc. (PRAX) trades at a EV/Sales of 812×. Over the past ten years it has ranged from 0.0× (December 2023) to 1,227× (August 2026); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 115× | 156.57% |
| FY2023 | 44.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 115× | (74.65%) |
| Sep 2024 | 455× | 90.10% |
| Jun 2024 | 239× | (13.58%) |
| Mar 2024 | 277× | 516.10% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CORT Corcept Therapeutics Incorporated compare | 7.6× |
| AXSM Axsome Therapeutics, Inc. compare | 7.6× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 11.2× |
| KRYS Krystal Biotech, Inc. compare | 17.0× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 24.3× |
| CYTK Cytokinetics, Incorporated compare | 65.9× |
| PRAX Praxis Precision Medicines, Inc. | 812× |
| SYRE Spyre Therapeutics, Inc. compare | 7,143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)